Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated US FDA label
Kidney dosing: Atorvastatin (single-agent)Show full dosing details
- eGFR ≥60
- No adjustment (label).
- eGFR 30–59
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- eGFR 15–29
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- eGFR <15 (not on dialysis)
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- Hemodialysis (intermittent)
- No dose adjustment (not dialyzed; label). KDIGO: do not start a statin in most patients already on dialysis; continue if already taking one at dialysis initiation.
- Peritoneal dialysis
- No label adjustment; no PD data.
- CRRT
- No data in label.
- Dialyzable? Not expected to be significantly removed by hemodialysis (label).
- Monitoring Muscle symptoms (myopathy, rhabdomyolysis); renal impairment is a risk factor (label).
From the Atorvastatin monograph (renalcarematters.com, reviewed).
Use: In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia… US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Contraindications
- Active liver disease or unexplained transaminases above 3 times the upper limit
- Pregnancy, breastfeeding, women of childbearing potential without contraception
- Glecaprevir/pibrentasvir
- Hypersensitivity
Dosing: Adult
- Hypercholesterolemia or mixed dyslipidemia; prevention of cardiovascular events: 10/10 mg to 10/80 mg once daily; titrate at intervals of 4 weeks or more; 2 hours before or 4 hours after a bile acid sequestrant
Dosing: Altered kidney function
Neither component needs a kidney dose adjustment: atorvastatin is eliminated in bile and is unaffected by kidney disease, and ezetimibe exposure rises only about 1.5-fold in severe kidney impairment. The Irish label sets no kidney adjustment. Muscle toxicity risk is driven by dose and interacting drugs. It has no US FDA label.
Kidney function measure: SmPC sets no kidney adjustment; pharmacokinetic data use creatinine clearance (CrCl ≤30 mL/min/1.73 m2). Bands shown on CrCl.
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 10/10 mg once daily; titrate at intervals of 4 weeks or more up to 10/80 mg (SmPC).
- CrCl 30–59 mL/min
- No dose adjustment in kidney impairment (SmPC). Atorvastatin is unaffected by kidney disease; ezetimibe AUC about 1.5-fold higher at CrCl ≤30.
- CrCl 15–29 mL/min
- No dose adjustment in kidney impairment (SmPC). Atorvastatin is unaffected by kidney disease; ezetimibe AUC about 1.5-fold higher at CrCl ≤30. KDIGO 2013 lists atorvastatin 20 mg/day as the dose studied in CKD trials; higher doses are not proven safe in advanced CKD, so avoid high doses at eGFR <30.
- CrCl <15 mL/min (not on dialysis)
- No dose adjustment in kidney impairment (SmPC). Atorvastatin is unaffected by kidney disease; ezetimibe AUC about 1.5-fold higher at CrCl ≤30. KDIGO 2013 lists atorvastatin 20 mg/day as the dose studied in CKD trials; higher doses are not proven safe in advanced CKD, so avoid high doses at eGFR <30.
- Hemodialysis (intermittent)
- No label adjustment (atorvastatin unaffected by kidney disease). KDIGO 2013: do not start a statin or statin/ezetimibe in patients already on dialysis; continue it if already taking it at dialysis start.
- Peritoneal dialysis
- No label adjustment; no PD data. KDIGO 2013: do not start a statin or statin/ezetimibe in patients already on dialysis; continue it if already taking it at dialysis start.
- CRRT
- No data; usually continued or held per clinical context.
- Dialyzable? Not stated (both highly protein-bound; removal unlikely).
- Monitoring Liver function tests before starting and periodically (reduce or stop if transaminases stay above 3 times the upper limit). Creatine kinase if muscle symptoms: do not start if CK is above 5 times the upper limit; stop if above 10 times, or above 5 times with symptoms (SmPC 4.4).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (March 2026). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not established in children (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg, 20 mg/10 mg, 40 mg/10 mg
Registered products in the Philippines
16 products registered with the Food and Drug Administration (FDA) Philippines list Atorvastatin + Ezetimibe as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products16
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ATOREZEAtorvastatin (as calcium) + Ezetimibe | 10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Ajanta Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc. | DRP-15944-02 | Oct 2, 2029 | |
AtorezeAtorvastatin (as calcium) + Ezetimibe | 20 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Ajanta Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc. | DRP-15945-01 | Oct 2, 2029 | |
AtorzetAtorvastatin (as calcium) + Ezetimibe | 10 mg / 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Importer: EuroAsia Pharmaceuticals Inc.Trader: Tunic Healthcare | DRP-7785 | Jul 21, 2032 | |
Atorzet 20Atorvastatin (as calcium) + Ezetimibe | 40 mg / 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan | Euroasia Pharmaceuticals, Inc. | DR-XY48270 | Aug 10, 2027 | |
AtozetEzetimibe + Atorvastatin (As Calcium) | 10mg/80mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's), Physician Sample: Alu/Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | MSD International GmbH (Singapore Branch)Singapore | Organon (Philippines) Incorporated | DR-XY46092 | Oct 8, 2031 | |
AvamedAtorvastatin (as calcium) + Ezetimibe | 10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Pharma Hub CorporationImporter: AMB HK Enterprises Inc. | DRP-15944-03 | Oct 2, 2029 | |
AvamedAtorvastatin (as calcium) + Ezetimibe | 20 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Pharma Hub CorporationImporter: AMB HK Enterprises Inc. | DRP-15945-03 | Oct 2, 2029 | |
AVATOR MAXAtorvastatin (as calcium) + Ezetimibe | 20mg/10mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt Ltd.India | Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc. | DRP-15945-04 | Oct 2, 2029 | |
AVATOR PLUSAtorvastatin (as calcium) + Ezetimibe | 10mg/10mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt Ltd.India | Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc. | DRP-15944-04 | Oct 2, 2029 | |
EztorAtorvastatin (as calcium) + Ezetimibe | 10 mg/10 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15944 | Oct 2, 2029 | |
EztorAtorvastatin (as calcium) + Ezetimibe | 20 mg/10 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. LtdIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15945 | Oct 2, 2029 | |
LiptruzetEzetimibe + Atorvastatin (as calcium) | 10mg/10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) (Physician’s Sample) | RxVAT-exempt | MSD International GmbH (Singapore Branch)Singapore | Organon (Philippines) Incorporated | DR-XY46089 | Oct 8, 2031 | |
LiptruzetEzetimibe + Atorvastatin (as calcium) | 10mg/20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) (Physician’s Sample) | RxVAT-exempt | MSD International GmbH (Singapore Branch)Singapore | Organon (Philippines) Incorporated | DR-XY46090 | Oct 8, 2031 | |
LiptruzetEzetimibe + Atorvastatin (as calcium) | 10mg/40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) (Physician’s Sample) | RxVAT-exempt | MSD International GmbH (Singapore Branch)Singapore | Organon (Philippines) Incorporated | DR-XY46091 | Oct 8, 2031 | |
Torezib 10Atorvastatin (as calcium) + Ezetimibe | 10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc. | DRP-15944-01 | Oct 2, 2029 | |
Torezib 20Atorvastatin (as calcium) + Ezetimibe | 20 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc. | DRP-15945-02 | Oct 2, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Glecaprevir/pibrentasvir | Avoid | Large rise in statin exposure. | Contraindicated. |
| Fusidic acid (systemic) | Avoid | Rhabdomyolysis, including deaths. | Contraindicated; restart statin 7 days after the last fusidic acid dose. |
| Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole), tipranavir/ritonavir | Avoid | Higher atorvastatin levels; myopathy. | Avoid; if unavoidable use lower doses (tipranavir/ritonavir: maximum 10/10 mg). |
| Elbasvir/grazoprevir, boceprevir | Adjust or monitor | Higher atorvastatin levels. | Maximum 10/20 mg. |
| Moderate CYP3A4 inhibitors (erythromycin, diltiazem, verapamil, fluconazole) | Adjust or monitor | Higher atorvastatin levels. | Lower maximum dose; monitor. |
| Gemfibrozil, fenofibrate | Avoid | Myopathy risk. | Not recommended. |
| Cyclosporine | Adjust or monitor | Higher ezetimibe and atorvastatin levels. | Use with caution; monitor cyclosporine levels. |
| Warfarin and other coumarins | Adjust or monitor | INR change. | Monitor INR. |
| Colchicine | Adjust or monitor | Myopathy reported. | Use with caution. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Diarrhea
- Myalgia
Serious
- Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy
- Hepatic failure
- Anaphylaxis; Stevens-Johnson syndrome, toxic epidermal necrolysis
- Myasthenia gravis
Monitoring parameters
- Liver function tests before starting and periodically (reduce or stop if transaminases stay above 3 times the upper limit). Creatine kinase if muscle symptoms: do not start if CK is above 5 times the upper limit; stop if above 10 times, or above 5 times with symptoms (SmPC 4.4). Kidney
- Liver tests before starting and periodically
- CK if muscle symptoms
- Lipids at 4 weeks or more after a dose change
Pharmacokinetics
Key PK parameters
| Half-life | Ezetimibe about 22 hours; atorvastatin about 14 hours (inhibitory activity 20 to 30 hours) |
|---|---|
| Half-life in kidney failure (ESKD) kidney | Atorvastatin unaffected; ezetimibe AUC about 1.5-fold at CrCl ≤30 |
| Metabolism (CYP, transporters) | Ezetimibe glucuronidated; atorvastatin CYP3A4 |
| Active metabolites | Ezetimibe glucuronide; atorvastatin hydroxy metabolites |
| Renal excretion kidney | Ezetimibe 11% in urine (78% feces); atorvastatin mainly biliary |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Ezetimibe/Atorvastatin Krka 10/20 mg SmPC (PA1347/116/002) [HPRA (Ireland) product information, March 2026; no US FDA label]. https://assets.hpra.ie/products/Human/41397/Licence_PA1347-116-002_02032026141340.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- KRKA, d.d.. (2026). Ezetimibe/Atorvastatin Krka 10 mg/20 mg film-coated tablets [Summary of product characteristics, licence PA1347/116/002; text revised March 2026]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/41397/Licence_PA1347-116-002_02032026141340.pdf
- Wanner, C., & Tonelli, M. (2014). KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney International, 85(6), 1303–1309. https://doi.org/10.1038/ki.2014.31
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .



